APPLIED INITIATIVES
Our current focus includes two applied medical initiatives in Greater China with near-term commercialization potential.
Early Lung Cancer Screening
APPLIED INITIATIVE 1
Authorized Import and Distribution Rights | Non-Clinical
This initiative focuses on early-stage lung cancer screening technologies, with an emphasis on blood-based risk assessment and early detection workflows. The program does not involve direct clinical diagnosis or treatment. All testing and clinical validation are conducted by downstream, QUEST-certified licensed laboratories (e.g., KingMed) or other organization.
Authorization: We are an authorized Greater China partner of Hawkeye Bio for product introduction and applied deployment support.
Rights & Scope: Exclusive Greater China import and distribution rights, covering Mainland China, Hong Kong, and Macau, including product introduction, market access coordination, and downstream partner enablement.
Start Date: January 1, 2026
Commercial Objective: Scalable applied deployment with an expected seven-figure HKD revenue potential over time.
Partner Access: Click the logo below (or the blue text above) to visit our partners’ official websites.
Applied Regenerative (& Longevity-Related) Medicine
APPLIED INITIATIVE 2
High-End Cross-Border Medical Referral | Non-Clinical
This initiative focuses on enabling access for high-net-worth individuals to advanced regenerative and longevity-related medical services in Japan. The program does not involve clinical practice, diagnosis, or treatment. All medical services are delivered directly by licensed Japanese medical institutions and physicians. Our role is limited to information support, service pathway arrangement, and cross-border access facilitation.
Medical service categories include, but are not limited to: (1) regenerative medicine–based interventions, e.g., corneal, cardiac, meniscus, ovarian, and neural regeneration, (2) longevity and anti-aging medicine, (3) functional and recovery-oriented treatments, (4) advanced health optimization programs, and (5) aesthetic and exosome-based services.
Authorization & Partners: We work with the following institutions to support applied access and service facilitation:(1) Fujita Health University (Main Campus), (2) Fujita Health University Tokyo Advanced Medical Research Institute / Haneda Clinic, (3) Woman Life Clinic, etc.
Rights & Scope: Non-exclusive applied access and coordination support for Greater China clients, including Mainland China, Hong Kong, and Macau.
Start Date: December 1, 2025
Commercial Objective: Scalable applied deployment with an expected six-figure HKD revenue potential over time.
Partner Access: Click the logo below (or the blue text above) to visit our partners’ official websites.
RESEARCH INITIATIVES
In parallel, two research-driven initiatives are being developed within practitioner-led, regionally grounded research contexts to inform future platform expansion.
Human-Shaped Robot with Touchscreen
RESEARCH INITIATIVE 1
Intellectual Property Status | Patent
A Chinese utility model application covering a human-shaped robot with a touchscreen-based interaction interface was filed in October 2025. The Hong Kong short-term patent application right related to this technology has been acquired and will be exercised by the company, providing localized intellectual property protection in Hong Kong. The robotic system is intended to be used in combination with an emotional companionship virtual human for older adults with cognitive impairment, forming a human-centric interaction solution.
This positioning aligns with current market and investment interest in human-oriented and emotionally responsive robotics.
Funding Plan (Proposed)：
The project will primarily seek venture capital investment, leveraging growing market interest in human-centric and emotionally responsive robotics. Public funding may be considered selectively.
Data-Driven Rare Earth Recycling from Medical Waste
RESEARCH INITIATIVE 2
Intellectual Property Status | Grant
The project aims to improve transparency and efficiency in evaluating recycling pathways for medical and high-value industrial equipment by integrating diverse technical information into a structured analytical framework. Through advanced data analytics and human-AI collaboration, it supports evidence-based decision-making for circular economy applications while reducing uncertainty and trial-and-error costs in technology selection.
Funding Plan (Proposed):
Target Programme: Hong Kong Innovation and Technology Fund
Indicative Funding Scale: HKD 2-3 million
Project Duration: 24 months